---
title: "Huaxia Eye Hospital Group Co.,Ltd. (301267.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301267.SZ.md"
symbol: "301267.SZ"
name: "Huaxia Eye Hospital Group Co.,Ltd."
industry: "Health Care Facilities"
---

# Huaxia Eye Hospital Group Co.,Ltd. (301267.SZ)

| Item | Detail |
|------|--------|
| Industry | Health Care Facilities |
| Location | CN Market |
| Website | [www.huaxiaeye.com](https://www.huaxiaeye.com) |

## Company Profile

Huaxia Eye Hospital Group Co.,Ltd. operates an ophthalmic medical chain in China and internationally. The company provides general ophthalmology diagnosis and treatment services for patients with ophthalmic diseases; and myopia prevention and intervention work to the public. It offers services in th...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:09.000Z

**Overall: C (0.41)**

**Industry**: Health Care Facilities

| Metric | Value |
|--------|-------|
| Industry Ranking | 4 / 9 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.60% |  |
| Net Profit YoY | -16.62% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.59 |  |
| Dividend Ratio | 1.66% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 15.55B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 4.12B |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.48% | B |
| Profit Margin | 10.72% | B |
| Gross Margin | 45.18% | B |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.60% | C |
| Net Profit YoY | -16.62% | D |
| Total Assets YoY | 1.29% | C |
| Net Assets YoY | 2.83% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 932.64% | B |
| OCF YoY | 0.60% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.51 | C |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 23.95% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Huaxia Eye Hospital Group Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.48%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "10.72%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "45.18%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.60%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-16.62%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.29%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.83%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "932.64%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "0.60%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.51",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "23.95%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Aier (SZ.300015) | B | C | B | B | C | B |
| 02 | Sanbo (SZ.301293) | C | B | C | B | B | B |
| 03 | INKON Life (SZ.300143) | C | B | C | B | B | B |
| 04 | Huaxia Eye (SZ.301267) | B | C | C | B | C | C |
| 05 | Innovative Medical (SZ.002173) | D | D | C | A | D | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 35.22 | 2/9 | 38.59 | 36.94 | 34.65 |
| PB | 2.59 | 2/9 | 2.91 | 2.74 | 2.66 |
| PS (TTM) | 3.78 | 5/9 | 4.15 | 3.92 | 3.82 |
| Dividend Yield | 1.66% | 2/9 | 1.17% | 1.06% | 0.57% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-10-30T16:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.51 |
| Highest Target | 24.50 |
| Lowest Target | 21.08 |

## References

- [Company Overview](https://longbridge.com/en/quote/301267.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301267.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301267.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.